The badger culls planned to take place in West Somerset and West Gloucestershire this year have been postponed until 2013.
The postponement came at the request of The National Farmers Union (NFU), following new survey results which revealed higher than anticipated badger numbers in the two pilot areas (4,300 in West Somerset and 3,600 in West Gloucestershire ).
The NFU informed Defra that in light of these new figures they could not be confident of removing the required minimum 70% of the badgers in the two pilot areas this autumn.
Defra agreed to postpone the pilot culls until summer 2013 to allow farmers to continue their preparations and have the best possible chance of carrying out the cull effectively.
Environment Secretary Owen Paterson said: "Despite a greatly increased effort over the last few days and weeks, the farmers delivering this policy have concluded that they cannot be confident that it will be possible to remove enough badgers based on these higher numbers and considering the lateness of the season. It would be wrong to go ahead if those on the ground cannot be confident of removing at least 70% of the populations. Today I have received a letter from the President of the NFU, on behalf of the companies coordinating the culls, explaining why they do not feel they can go ahead this year and requesting that they be postponed until next summer. In these circumstances, it is the right thing to do and, as the people who have to deliver this policy on the ground and work within the science, I respect their decision.
"The Government is determined to tackle bovine TB by all the means available to us. Now, in the next few months, we will ensure that the pilot culls can be implemented effectively, in the best possible conditions, with the right resources. Having looked at all the evidence over many years, I am utterly convinced that badger control is the right thing to do, and indeed the higher than expected badger numbers only serve to underline the need for urgent action. I remain fully committed to working with the farming industry to ensure that the pilot culls can be delivered effectively, safely and humanely next summer."
The Government and NFU say they will now continue to plan so that the pilots can go ahead in Summer 2013.
Ceva Animal Health has announced the launch of Cardalis for the treatment of canine heart failure caused by degenerative valvular heart disease.
Cardalis contains what the company says is a unique combination of benazepril and spironolactone in one tablet which provides "dual blockade" of the RAAS system.
Benazepril reduces the production of angiotensin II, which causes narrowing of the blood vessels, while spironolactone blocks the harmful effects of aldosterone, which include cardiovascular remodelling and fibrosis.
Cardalis tablets are small, beef flavoured and designed to be administered once a day with food. Each pot contains 30 tablets and there are three sizes available. Ceva says it should be given as part of standard heart failure therapy as soon as clinical signs, such as exercise intolerance, coughing or dyspnoea, appear.
Fraser Broadfoot, small animal product manager at Ceva Animal Health, said: "Through our clinical studies, it has been found that dogs receiving benazepril and spironolactone (compared with benazepril alone) have a better quality of life and, at any one time, are three times less likely to die from heart failure.
"We have also assessed 101 dogs in a field study that were prescribed Cardalis for three months, followed by separate benazepril and spironolactone tablets for two weeks. In the study, 97 per cent of dog owners found Cardalis easier to administer than the two separate tablets and 89 per cent of vets found Cardalis easier to prescribe."
For further information about Cardalis, or to receive marketing materials for the product (which include a waiting room poster and client information booklets), visit www.ceva.com.uk, or contact the practice support team on 01494 781510.
Norbrook Laboratories has launched a ready-to-use suspension version of its Cefenil antibiotic.
Cefenil RTU (ceftiofur) is a 50mg/ml suspension for injection, indicated for cattle and swine.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "Cefenil RTU is a broad spectrum injectable antibiotic offering fast and effective treatment of bacterial respiratory disease, foot rot and acute post-partum metritis in cattle as well as bacterial respiratory disease in swine. It offers a zero milk withhold and a 5-day meat withhold which is the shortest on the market."
Norbrook's Cefenil Powder and Solution for Injection has been available for a number of years for the treatment of cattle and swine. It has recently been indicated for the treatment of BRD in horses in the UK. Cefenil RTU will offer vets an additional choice in the treatment of BRD.
Dr McInerney added: "Cefenil is a tried and tested antibiotic which vets have been using for a number of years. We are delighted to extend the Cefenil range with a RTU suspension for cattle and pigs and adding an indication for horses to our Cefenil Powder and Solution for Injection. It gives vets a wider choice for the treatment of BRD with a product with which they are already familiar."
For further product information, visit www.norbrook.com.
The BSAVA reports that its Certificates in Medicine and Surgery have sold out in less than 5 minutes, beating the previous record of 20 minutes in their first year.
The Association says that whilst this is testament to the success and demand for its CPD, it is determined to find a way to avoid disappointing so many aspiring students - and after emergency talks over the weekend has decided to run a second intake of 30 students for each of the two programmes from January.
Dr Frances Barr, BSAVA's Academic Director, said: "Whilst we had only envisioned taking 30 new students onto each course this year, it quickly became clear that there is such a great appetite for this kind of accredited CPD in the profession right now. What a shame it would have been not to find a way to allow those ambitions to be fulfilled. So we are effectively going to run each programme twice in one year."
Quality control and sufficient student support is being met thanks to an overwhelming response from our teaching faculty and mentors. Dr Barr added: "BSAVA owes thanks to all those who lecture and work alongside our Certificate students. Without them we would not have been able to respond so quickly to this unprecedented demand".
The second programme will take place at two sites; BSAVA HQ in Gloucester, and the College of Animal Welfare in Huntingdon. Anyone who has not been able to take a place in the 2013 cohort will be offered priority registration for the 2014 in-take. For more information about BSAVA Certificates visit www.bsava.com or email administration@bsava.com.
The RCVS Disciplinary Committee has directed that the name of a Berkshire-based veterinary surgeon, previously convicted of four offences under the Animal Welfare Act 2006, should be removed from the RCVS Register of Veterinary Surgeons.
Dr Ohene-Gyan was convicted at Reading Magistrates Court on 13 June 2012 of offences involving causing unnecessary suffering to three dogs and a cat that he had treated whilst working at Woosehill Vets, Wokingham, between February and October 2011. These offences related to failing to provide adequate or appropriate veterinary care or treatment, or failure to investigate and address an animal's poor condition. He was sentenced to 21 weeks' imprisonment concurrently for each offence.
Dr Ohene-Gyan did not attend the one-day Disciplinary Committee hearing and was not represented, although College records showed that he was aware of the dates of the hearing, and had had opportunity to apply for an adjournment. In the absence of any known good reason for Dr Ohene-Gyan's non-attendance, the Committee concluded that it was in the interests of justice that the hearing go ahead.
In considering whether the Respondent's convictions made him unfit to practise as a veterinary surgeon, the Committee depended on the findings of the District Judge and the remarks she had made when sentencing. "I found as a matter of fact that some of your actions were taken simply to run up a bill for the owners of pets," she had said. "You were in a position of special responsibility, trusted by the owners of the animals to treat them appropriately and to alleviate their suffering. You ignored advice from staff. Several animals were affected by your cruel disregard of their welfare. Some of the cruelty arose due to your incompetence. You have demonstrated that you are not fit to be trusted with the care of animals."
The Disciplinary Committee Chairman, Professor Peter Lees, speaking on behalf of the Committee, said: "The Respondent's actions, motivated by financial gain, caused serious actual injury to the four animals over a prolonged period of time. Clients are entitled to expect that veterinary surgeons will treat animals in their care humanely and with respect, and make animal welfare their first priority. The Committee considers that the care described in the District Judge's findings demonstrated a total disregard for the professional responsibilities of a veterinary surgeon."
The Committee concluded that the removal of Dr Ohene-Gyan's name from the Register was the only appropriate and proportionate sanction in this case in order to protect the welfare of animals, maintain public confidence in the profession and uphold proper standards of conduct, and it directed the Registrar to do so.
Virbac has launched an iPhone app designed to support veterinary surgeons in the diagnosis of canine dermatological conditions.
Called Virbac-Derm-Diag it enables clinicians to create a clinical history (including photographs) of a patient then recommends a clinical chronological approach for the diagnosis of many of the canine skin diseases seen most commonly in practice. It also contains a library of downloadable monographs, videos and images of skin diseases which can be used to support discussions with owners about diagnosis and potential treatment regimes.
Chris Geddes MRCVS, Product Manager, said: "Dog skin disorders are among the most common health problems seen in practice and have a wide range of causative factors. We are really excited about the launch of the app, which should prove really useful as vets work through the various steps of history-taking and examination required to reach an accurate diagnosis.
It also provides a wealth of materials to help them explain the implications of diagnosis to owners and recommended treatment options."
Veterinary dermatologist Anthony Chadwick said: "This is an ideal app for those vets who have an interest in dermatology and want readily accessible information at their fingertips. The images of lesions are likely to be particularly helpful."
Virbac Derm-Diag, it is available by searching for 'Virbac' in the app store (or click here). The content is restricted to veterinary surgeons, who must register at www.virbacderm.com to gain an access code.
Virbac says an iPad version will be available within weeks and there are plans to launch the app on other platforms shortly.
Rimifin (carprofen), an NSAID marketed by Vetoquinol, has been given a new flavour to help increase compliance.
Robert Simpson, Product Manager for Rimifin said: "Pet owner compliance and involvement in chronic pain situations is critical to ensuring effective long term treatment. Ease of administration is also very important in this setting. The addition of this flavouring to this popular and cost effective NSAID will help to ensure that administration to the patient is as easy as possible for pet owners and vets."
To find out more about Rimifin please contact your Vetoquinol Territory Manager or call 01280 825424.
Virbac Animal Health has launched a twitter-based early warning system to alert vets and dog owners of cases of canine parvovirus (CPV) in their area. It is to go live on 1 November 2012.
@parvoalert is a twitter feed that updates followers on the geographic location of cases of the disease using the first half of the relevant postcode. The company is asking vets and owners learning of a case to tweet the first half of the postcode where it occurs to @parvoalert. Virbac will then retweet it to everyone else following @parvoalert. The company is also advising vets and owners to check the feed regularly for news of cases. The service is free.
Virbac says that when it hears of a case, it will also provide practices in 'at-risk' areas with a 'Parvo-alert' Pack, containing a range of tools and support materials to help them alert dog owners. These include waiting room posters, leaflets, stickers and template text for newsletters.
The Veterinary Director of Battersea Dogs & Cats Home, Shaun Opperman, said: "As recent viewers of ITV1's 'Paul O Grady: For the Love of Dogs' may have seen, parvovirus causes dreadful suffering to dogs. Unfortunately many people still aren't vaccinating their dogs, so we see cases on a regular basis and it's vital that owners vaccinate their dogs, are aware of the disease and remain vigilant for the early signs."
Simon Boulton MRCVS, Product Manager at Virbac, said: "One of the problems in tackling canine parvovirus is that little information is shared on the frequency and location of cases so, in some ways, it's a hidden problem. While it's not as common as some other infectious diseases, when outbreaks occur, as they did earlier this year in South Wales and Oxford, the disease proves fatal in around half of diagnosed dogs."
Once @parvoalert is established, Virbac says it aims to build it into a comprehensive web-based CPV resource, featuring background on the prevention and treatment of the disease; comment from veterinary experts and downloadable practice support materials.
Simon continued: "It's heart-breaking for owners to lose their pets in this way and to see them suffer from a disease that could easily have been prevented. We hope @parvoalert will help to raise awareness of the fact that CPV continues to represent a significant threat to unvaccinated dogs. It will benefit all practices in areas affected as they will receive a Parvo-alert Pack, which they can use to encourage their clients to get their dogs vaccinated and look out for signs of the disease."
The BVA has welcomed the decision to prohibit the advertising of antimicrobials directly to animal keepers from 2013 in a bid to reduce antimicrobial resistance.
The Veterinary Medicines Directorate (VMD) announced that the Veterinary Medicines Regulations will be revised next year. The change has come as a result of the European Commission's view that the UK did not correctly transpose the European Directive 2001/82/EC which prohibits the advertising of certain veterinary medicinal products to the 'general public'.
When the VMD consulted on proposals to restrict the advertising of antimicrobials to farmers in 2010 the BVA supported the measure as a sensible approach to the responsible use of antimicrobials.
In a letter to stakeholders the VMD explained that: "A number of interested parties from veterinary medicine hold the view that the advertising of antibiotics to keepers of animals leads to undue pressure to prescribe newer antibiotics, which can often be important in human medicine and are associated with the development of multiple resistances."
Peter Jones, President of the BVA, said: "The BVA has consistently argued for the restriction of advertising of antimicrobials to animal keepers and we believe this is the right decision.
"New antimicrobials are heavily advertised by pharmaceutical companies and there can be undue pressure put on veterinary surgeons by clients who want to try new products that promise good results, but which may not be appropriate from the point of view of responsible use.
"Antimicrobial resistance is a very serious issue for both animal and human health and we are pleased that the European Commission and the VMD have taken the view that the Regulations need to be revised.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets will continue to work with their farm clients to ensure antimicrobials are used prudently and responsibly."
Two veterinary surgeons from the Animal Health Trust have won international awards for outstanding work in diagnostic imaging at 16th International Veterinary Radiology Association (IVRA) meeting held in Bursa Turkey.
Dr Sue Dyson, Head of Clinical Orthopaedics at the AHT, was awarded the IVRA J Kevin Kealy Award, which recognises members of the IVRA who have made substantial, scientific contributions to veterinary radiology.
The Award, established in 2003, is named in honour of Emeritus Professor J. Kevin Kealy, organiser of the first meeting of the IVRA, the first President, and an Honorary Member of the Association.
Sue has lectured internationally and published more than 200 refereed papers in scientific journals, as well as being a major author and editor of four books. On receiving the award, she said: "I was hugely surprised to receive this award and feel extremely honoured."
Past president of the IVRA, Peter Lord, said: "It is hard to imagine that equine diagnostic imaging today would be the same without the contributions of Sue Dyson and her colleagues. She is an outstanding recipient of the J Kevin Kealy Award."
Ruth Dennis, Head of Diagnostic Imaging (pictured above right), was awarded the European Association of Veterinary Diagnostic Imaging (EAVDI) Douglas and Williamson Award, established in 1983, to recognise outstanding achievement within the field of veterinary diagnostic imaging.
Ruth was President of the EAVDI between 2000 and 2002 and her long standing contributions to the association have been recognised with this award.
Ruth said: "I am very honoured to receive this award, especially since, as a vet student in Cambridge in the late 1970s, I was taught by Sidney Douglas and David Williamson, who were pioneers of veterinary radiology."
Nuria Corzo-Menendez, current EAVDI President, said: "Ruth's contributions to veterinary diagnostic imaging are vast and we will always be grateful for such great additions to our field."
Animalcare has released further information about Vitofyllin (propentofylline), its new CNS stimulant for dogs.
According to the company, Vitofyllin helps restore vitality and willingness to exercise, especially in the senior dog, by improving peripheral and cerebral vascular blood circulation. It is indicated to help improve dullness, lethargy and overall demeanour in dogs. In addition it has a bronchodilatory activity equivalent to amilophylline (a salt of theophylline)
Animalcare says that with dogs living longer, age-related problems are on the increase. The company highlights the example of Cognitive Dysfunction Syndrome (CDS), a neurodegenerative disease that affects older dogs. CDS is characterised by various pathological processes with signs that include disorientation, changing interaction with people or other pets, sleep-wake cycle alterations, soiling in the house and decreased activity levels.
The company says these subtle behavioural changes are unlikely to be picked up at a routine annual check. Indeed, in one study 75% of owners of dogs aged over 7 reported at least one behavioural sign consistent with CDS, however only 12% reported their concerns to a vet.2
Vitofyllin is available in 50mg and 100mg strengths in blister packs containing 56 tablets. Presented as 'easy to administer' four-way split cross-snap-tabs which can be divided into halves or quarters to enable more accurate dosing to be achieved whatever the weight of animal, even down to 2.5kg bodyweight.
Vitofyllin is POM-V licensed and has a 3 year shelf-life. Waiting room posters and client leaflets are available to support recognition of behavioural signs by clients and practice staff.
Further iinformation, and details about a special launch offer are available from local Animalcare representatives.
Reference
Royal Canin has announced it is to launch Catom, a piece of software developed to help educate cat owners during veterinary consultations, at this year's London Vet Show.
Initially, the software will be available for PC and Mac, with iPad and Android versions coming by the end of the year.
You can can find out more by visiting Royal Canin's stand at the London Vet Show, where the company says it will have a large touch-screen TV displaying the software, along with laptop demos running throughout the exhibition.
Dorwest Herbs has launched its annual 'Dorwest Say Relax' fireworks phobia campaign, which includes free promotional packs for practices.
The promotional packs, which contain a poster, leaflets, flashing badges and a 'Dorwest Say Relax' t-shirt, being given free to the first 100 practices that request a product box (containing licensed Scullcap & Valerian Tablets and Organic Valerian Compound at a discounted price) from the company.
In addition, Dorwest is running a seemingly popular consumer facebook competition to find the most relaxed dog in the nation, the winner of which will be sent on a pet-friendly luxury weekend break.
Finally, the company is writing a blog written from the perspective of Merlin, the dog used in its logo - http://merlintakescontrol.wordpress.com - though quite who is going to read it, or why, is slightly beyond me.
The Animal Health Trust has presented the results of a study which has identified a significant link between hind limb lameness and saddle slip, showing consistent saddle slip in some horses with hind limb lameness, even when the lameness is fairly subtle and difficult to detect.
According to the AHT, saddle slip in sports horses is a well-recognised problem that can occur for a variety of reasons, including asymmetry in the shape of the horse's back, riders sitting crookedly and ill-fitting saddles. Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust, had also observed that saddle slip may occur because of hind limb lameness. The intention of the study, therefore, was to find out more about the interrelationships between the horse, saddle and rider and to document the frequency of occurrence of saddle slip in horses with hind limb lameness compared with other horses.
The research was undertaken by Sue Dyson and Intern Line Greve and was presented at the British Equine Veterinary Association (BEVA) Congress last month. It is thought to be the first study of its kind, and was supported by the Saddle Research Trust (SRT). The SRT is a charitable organisation, aiming to facilitate research and provide support as well as advice on the influence of the saddle on the welfare and performance of horses and riders.
The study assessed 128 horses of varying size, age and type. The degree of lameness of each horse was graded; back shape and symmetry were measured and saddles assessed for symmetry and fit. Each horse was ridden by at least two riders and rider straightness plus weight were recorded. The grade of saddle slip, whether it occurred with more than one rider, and whether saddle slip was influenced by the direction of movement or the diagonal on which the rider was sitting were also noted.
The saddle consistently slipped to one side in 54% of horses with hind limb lameness, compared with 4% of horses with fore limb lameness, 0% with back pain and/or sacroiliac joint region pain and 0% of non-lame horses. Diagnostic analgesia was subsequently used to abolish the hind limb lameness and this eliminated the saddle slip in 97% of cases.
Sue said: "Our findings emphasise the need to educate owners, veterinarians, physiotherapists, trainers, riders and saddle fitters that saddle slip is frequently an indicator of lameness, not necessarily a manifestation of an ill-fitting saddle or asymmetric shape of the horse's back. Detection of saddle slip provides an opportunity for the owner, riders and trainers to detect low-grade and subclinical lameness, with important welfare consequences."
Further scientific studies are planned, with the support of the Saddle Research Trust, in order to build on these findings. To this end the SRT is currently seeking an honorary fundraiser to help secure ongoing financial support. For further information contact Anne Bondi on 07775 912202 or email annebondi@me.com.
1An investigation of the relationship between hindlimb lameness and saddle slip, L. Greve and S.J. Dyson, Centre for Equine Studies, Animal Health Trust, Lanwades Park, Kentford, Newmarket, Suffolk, CB8 7UU, UK.
The Feline Advisory Bureau (FAB) has teamed up with Agria Pet Insurance to provide insurance cover for cats in the UK, with each policy generating a donation to the work of FAB and its International Fund for Cat Welfare.
Ross Tiffin, FAB's Strategy and Business Adviser said: 'In Agria, we have found a respected company that shares our ethos - it believes in sharing information to makes cats' lives better. One of the leading pet insurers in the world, Agria has been insuring pets since 1890 and has shared information on longevity and disease patterns with university researchers for many years.'
Claire Bessant, Chief Executive of FAB said: 'FAB has always been an enthusiastic supporter of health insurance for cats - we want cats to receive the best treatment without owners having to worry about the cost. Our support has now taken on a practical form in the shape of a general pet insurance guide and, through working closely with Agria, by providing cat owners with an excellent insurance option.'
To view A fabcats guide to cat insurance go to www.fabcats.org/catinsurance. The guide gives generic advice on choosing insurance.
For more information on Fabcats Cat Insurance from Agria go to www.fabcats.org/catinsurance or call Agria on 0800 369 9441.
Elanco Companion Animal Health has announced that its Duvaxyn IE and IE-T Plus vaccines have been licensed for active immunisation against OIE recommended clade 1 and clade 2 equine influenza strains, the first vaccines to be so licensed.
The company says the updated license is a result of a recent challenge study which demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to induce cross protection against clade 2 strain A/equi-2/Richmond/1/07 (H3N8) two weeks after two doses of the primary course1 were given. Cross-protection was further supported by another study2 measuring serum antibody response to the Richmond '07 strain 52 weeks after the three dose primary vaccination course.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade3.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health UK, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of our challenge study and subsequent licence update provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE has identified as being of concern.
"Further reassurance is also given with the confirmation in our study that Duvaxyn IE-T Plus elicits a cell mediated immune response, recognised to play an important role to aid in viral clearance and further enhances protection against strains circulating in the field." 4
The live virus challenge study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two doses of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Duvaxyn IE-T Plus is the only inactivated whole virus carbomer adjuvanted equine influenza vaccine in the UK. According to Elanco, experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins including the conserved nucleoprotein, which shows no antigenic drift, in the vaccine5.
References
The RCVS Charitable Trust has released the results of a survey that suggests a lack of available, high-quality research could be hampering the implementation of evidence-based medicine (EVM) in veterinary practice.
Of the 70 survey respondents, although 70% said they were familiar with the concepts of EVM, only 36% said that they always used EVM principles or that EVM principles were deeply embedded within their practices. When asked about the barriers to implementing EVM, many vets commented that there was a lack of high-quality research available to them.
Trust director, Cherry Bushell said: "This survey was relatively small as our intention is for it to help spark discussion at our forthcoming symposium 'The Sceptical Vet: Eminence or Evidence? Finding the best way forward for the veterinary profession'. We want to consider the possibility of developing a range of evidence-based resources for the veterinary profession, so it's interesting to hear vets commenting about the lack of an available, high-quality evidence base."
All those completing the Trust's survey were entered into a prize draw for a chance to have their travel expenses to the event reimbursed. Veterinary surgeon Ariel Brunn (top right) from Vets Now, Maidenhead, was the winner. She said: "I'm really looking forward to this Symposium and the discussion that will come with it - along with clinical governance, evidence-based practice provides a means to offer the best care for our veterinary patients. Having been a practising vet for less than 5 years, I'm excited to learn more about how EVM can be incorporated into veterinary practice and I'm certainly pleased to have won the prize draw to support my travel to this event."
This symposium will take place on Tuesday 30 October 2012, at Church House Conference Centre, London. A limited number of places are still available for practising veterinary surgeons and veterinary nurses only via the Trust (a.doorly@rcvstrust.org.uk or 0207 202 0741). For more information visit http://trust.rcvs.org.uk/grants-and-collaborations/the-sceptical-vet-eminence-or-evidence.
Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.
Peter Harlech Jones has been elected President of the British Veterinary Association for 2012/2013. The ceremony took place during the Annual General Meeting of the BVA at the close of its Annual Congress, held in the Merseyside Maritime Museum in Liverpool.
Mr Jones, an international consultant on veterinary medicines, was born and raised in North Wales where he attended the Sir Huw Owen School in Caernarfon. He qualified from the University of Liverpool Veterinary School in 1971. After several years in practice in Wales and London - plus a spell in Ontario, Canada - Peter joined the pharmaceutical industry and spent 20 years in the animal health business both in the UK and overseas working in the fields of research and development and also regulatory affairs.
In 1995 he was appointed the first head of the Veterinary Division at the newly created European Medicines Evaluation Agency (EMEA) in London, playing a leading role in the creation of the new European regulatory system and working at the centre of European institutions. His last post before semi-retirement in 2008 was as head of the global animal health industry association, the International Federation of Animal Health (IFAH).
Within the BVA Peter has served on the Veterinary Policy Group and as chair of the Medicines Group and is a former secretary and chairman of the Association of Veterinarians in Industry (AVI). He participates in the work of the Federation of Veterinarians of Europe (FVE) and acts as a consultant to GALVmed whose aim is to make livestock vaccines, diagnostics and medicines accessible to those in developing countries for whom livestock is a lifeline.
Mr Jones said: "My background is in pharma research and international regulatory affairs and I am confident that my experience will be useful as we anticipate the new EU Animal Health Law and medicines legislation. But I am driven to do much more for the veterinary profession than just in those fields.
"The word 'value' really began to resonate for me when I started thinking of my theme for the year ahead as President of BVA.
"In whatever role we play vets are adding value in so many areas of our professional lives to society at large in a huge and significant contribution to the public good. I firmly believe that we, as an association and as a profession, must use every opportunity to reinforce the message about the value we give in all aspects of our work, and to believe in ourselves.
"I want to see a greater appreciation for what we do and what we contribute, and BVA will lead from the front.
"Looking ahead it will be a busy year for all of us. But I am confident that we have the teams in place - through our committees and council, our regional representatives, our divisions and beyond - to do our wonderful profession proud.
"I am certainly very proud to be standing here today and I am committed to working hard for all our members as their President."
The BVA Officer Team for 2012/13 is Peter Harlech Jones (President), Carl Padgett (Past President), and Robin Hargreaves (President Elect)
The BVA has announced that from 2013, its annual Congress will take place at the London Vet Show.
The association says that the move is being done to bring together political debate and clinical CPD on a large scale and to ensure that the BVA can reach an even wider audience with its representative and educational services.
The BVA and the Vet Show teamed up last year at London Vet Show 2011 to announce the launch of the BVA Careers Fair, which will be hosted at this year's London Vet Show on 15-16 November, and the start of a partnership that would ensure discounted Vet Show rates for BVA members.
2013 will also see two new clinical streams added to the London Vet Show programme creating a comprehensive CPD event for vets in small and mixed practice. Cattle and equine streams for mixed practitioners will be delivered by the BVA to run alongside the popular companion animal stream provided by the Royal Veterinary College.
The partnership will also see substantial discounts being offered to BVA members.
BVA President Carl Padgett said: "BVA's number one value is that our members are at the heart of everything we do. We know that members require good value, high quality and relevant CPD and we believe that our new partnership with the London Vet Show offers the best opportunity for us to provide members with exactly what they want.
"It's a significant move for BVA but one that makes complete sense. From 2013 we will be bringing together the contentious issue streams that are the bedrock of BVA Congress, with a high quality clinical CPD programme covering large and small animals, and one of the biggest and best veterinary exhibitions.
"We know we haven't attracted the delegate numbers we would like to have done in recent years and by partnering with the London Vet Show we have the opportunity to reach a much greater audience. It's a very exciting step forward for BVA."
Rob Chapman, Event Director for the London Vet Show, said: "We are all delighted to be developing our relationship with the BVA. To be able to host such an established and prestigious event as the BVA Congress at the London Vet Show is an honour for the Vet Show.
"Combining the long-standing history of the BVA with the rapidly developing reputation of the Vet Show gives us a great symbiotic relationship. The new clinical content that we will be working on together will help the event and that relationship even further offering great value for both Vet Show delegates and BVA members."
Invicta Animal Health has launched SynVet-50, a licensed synthetic Sodium Hyaluronate (HA), for intra-articular treatment of lameness caused by joint dysfunction associated with non-infectious synovitis in horses.
The product is Invicta's first licensed medicine.
According to the company, the functional mechanisms of HA are directly dependent on the molecular weight and concentration of HA. 1 Therefore, SynVet-50 has been formulated with a molecular weight of 1.5m Daltons which is the highest of any synthetic HA available in the UK.
Invicta says that at 20mg per ml, SynVet-50 is also the most concentrated HA available.
Storage is at ambient temperature.
SynVet-50 is a 2.5ml solution containing 50mg HA, conveniently presented in a 5ml glass syringe.
Rob Watkins, Managing Director of Invicta said: "We are excited to be launching our first licensed medicine in the UK. The management team of Invicta have over 10 years experience in this market which has allowed us to provide a product strongly focussed on the clinicians needs, not just in terms of technical ability, but also in convenience of presentation".
For further information see www.invictavet.com or phone 01403 791313
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The Kennel Club has announced that crossbreed dogs are to have their own event at Crufts for the first time next year.
For the first time in its twelve year history, the grand final of Scruffts, the crossbreed dog competition run by the Kennel Club, will culminate at Crufts at the NEC in Birmingham. The winners of the four Scruffts categories - Child's Best Friend, Golden Oldie, Prettiest Crossbreed Bitch and Most Handsome Crossbreed Dog - will battle it out for the ultimate title of Scruffts Family Crossbreed of the Year.
Scruffts, sponsored by James Wellbeloved, has held heats across the UK over the course of the year and the winners of each category in every heat have been invited to Discover Dogs in London to compete in the class finals on Saturday 10th November. Winners of the four classes at Discover Dogs will now go on to Crufts 2013, where they will compete for the overall Scruffts title.
Caroline Kisko, Secretary of the Kennel Club, said: "Scruffts is a fantastic competition and we're very much looking forward to seeing the four class winners come to Crufts for the final next year. We have had some fantastic Scruffts champions in the past and I am sure we can expect to see a really special dog take the title once again."
There is still time to qualify for the Scruffts class finals, with heats taking place at CSJ Canine Max 2012 in Cirencester Park on Saturday 13th October and the East of England Autumn Show in Peterborough on Sunday 14th October.
The inaugural Vet Charity Challenge, which took place on 15th September at the Royal Agricultural College in Cirencester, has raised at least £20,000 for charity.
Twenty-six teams of four people took part, spending seven hours walking, running, cycling, kayaking, orienteering, along with a few mental physical challenges along the way.
The Challenge started in the morning with a sprint to collect puzzles for teams to solve. This determined time slots when teams could attempt six mental and physical puzzles during the morning session. The teams then headed off on a walk or run around the surrounding countryside. The aim was to visit as many points on the map as possible. Each team could choose its own route. After lunch, the teams headed off again for the cycling stages, visiting places on the map in order to gain more points. Then finally it was onto the water for the kayaking stage.
The winning team was the Complete Animal from Hyde Park Veterinary Centre in London. Team captain Leah Morley said: "The event was great fun, really well organised, and all the teams seemed to have got right behind it. You really had to work as a team, playing to different peoples strengths both physically and mentally. Everyone had a fair chance of winning. We would really like to thank others in the practice and our clients who were massively generous in their support and sponsorship. Their response was quite inspirational and certainly had an impact in driving us to perform well. I think every practice should take part and we look forward to returning next year to defend our title."
All the teams enjoyed the day and met the challenges head on and were enthusiastic for the Vet Charity Challenge to continue next year. Head Nurse Angella McNellan from Glenbrae Veterinary Clinic in Bearsden, Glasgow said: "The Vet Charity Challenge has been brilliant fun, beautiful scenery, great challenges. It has really helped get fitter through training as a team after work during the summer. We cannot wait to do it all again next year."
Roger Dixon MRCVS from Ashbrook Equine Hospital in Cheshire said: "The Challenge has been great fun, we really enjoyed the teambuilding element. Also it was worth the pain to beat the farm team!"
Nicolette Hayward from team The Far Canals said: "The Vet Charity Challenge has been superb, enormous fun. We did absolutely no training and came in fourth, so we are very happy with that result."
Jason Rogers from BCF team Witness the Fitness said: "We really enjoyed the day, found it exhausting though, the kayaking was the toughest part, and we had quite a run back in the morning to get back in time."
To add to the level of exhaustion competitors were flung around the dance floor for a Ceilidh following a barbeque in the evening. The band consisted of organisers from the event including caller Brian Wright from Vets Now and competitors Nicolette Haywood and Jim Hughes.
For more information, see more photos and to register interest for the challenge in 2013 visit www.vetcharitychallenge.co.uk. Also follow Vet Charity Challenge and on Twitter @vetchallenge.
Petplan has announced that it has raised £1million for the Blue Cross in the past decade.
The funds have gone towards running a dozen rehoming centres for dogs, cats, horses and rabbits, as well as four major animal hospitals across the country.
Petplan offers four weeks free insurance to adopters of dogs, cats and rabbits from Blue Cross as well as many other animal charities across the UK. All animal charities who work with Petplan receive 10% of the premium for any full policies they generate. The company says that in 2011, it raised over £2million for animal charities this way.
Petplan says that in addition to creating additional funds for the charity, providing four weeks free pet insurance also gives charities peace of mind that if the pet should require veterinary treatment the adopter has the funds available to ensure the animal receives the care it needs. This also means that the animal is less likely to be returned to the charity because the adopter can't afford the veterinary fees or that the charity will be asked to help cover the cost of treatment.
Chief Executive of the Blue Cross, Kim Hamilton, said: "As a charity that does not receive any government or lottery funding, we rely solely on donations from the public and valuable funding from our corporate partners. Petplan understands that our primary focus is animal welfare and the income generated from working with them has enabled us to give even more pets a healthy life in a happy home."
Simon Masding, Petplan's Head of Sales and Partnerships said: "At Petplan we work with over 1,700 animal charities and therefore understand the financial struggles that charities face on a daily basis. Along with offering charities commission Petplan also run the Charity Cheque initiative. When a four weeks free pet insurance voucher is activated it automatically enters the charity into a monthly prize draw to win £500."
For more information on how your animal charity can work with Petplan please visit www.petplan.co.uk/charity or call Charityline on 0800 072 8877.